Pathway Therapeutics

What Pathway Therapeutics does

Pathway Therapeutics is a privately held, San Francisco-based small-molecule drug discovery company founded in 2008 that develops selective inhibitors of phosphoinositide 3-kinase (PI3-kinase) intended for the treatment of cancer and inflammatory diseases. The company's stated therapeutic focus is on isoform-selective PI3K inhibition, a target class with significant clinical and commercial interest but also a history of tolerability challenges, and its pipeline is positioned at the preclinical discovery stage with no products, approvals, or named candidates disclosed in the available data. Its underlying technology is rooted in medicinal chemistry rather than in silico or AI-driven discovery, and there is no evidence of a commercial platform, diagnostic component, or computational biology stack. No go-to-market mechanics, pricing model, or customer relationships are documented, consistent with a research-stage operating posture.

The company has raised approximately $24.4 million across five recorded financing events between 2008 and 2013, with Talu Ventures and GBS Ventures as repeat lead investors and a one-time participation by New Zealand Venture Investment Fund in 2010. Headcount is reported at 11–50 employees, and no management team, board composition, partnerships, or licensing deals are disclosed in the current data set. Critically, no funding, partnership, product, or leadership events have been recorded since the small $400,000 raise in March 2013 — a 12+ year gap that materially affects any read of the company's current operating status, pipeline momentum, or fundraising capacity. Investors analyzing the asset should treat the absence of post-2013 signals as the single most important data point when assessing viability.

Name

Pathway Therapeutics

Legal name

Pathway Bible Church

Website

https://pathwaytx.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Pathway Therapeutics is a San Francisco-based, privately held small-molecule drug discovery company founded in 2008 that develops selective PI3-kinase inhibitors for cancer and inflammatory diseases. It is research-stage, with no commercial products or partnerships disclosed in the available data.

Ownership category

akta.pro rank

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Pathway Therapeutics develops selective small-molecule inhibitors of PI3-kinase intended for the treatment of cancer and inflammatory diseases. The company focuses on pharmaceutical research and development of targeted kinase inhibitor therapeutics for oncology and inflammation indications.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves5 records

Expansion highlights2 records

Broad incumbents

• Gilead Sciences: Acquired Calistoga Pharmaceuticals and commercialized idelalisib (Zydelig), a first-in-class PI3K delta inhibitor. Has experienced significant safety setbacks in the class, shaping the competitive landscape.
• Novartis: Approved alpelisib (Piqray), a selective PI3K alpha inhibitor, for HR+/HER2- breast cancer. A broad incumbent with deep oncology infrastructure that competes directly in the PI3K space.
• Exelixis: Small-molecule oncology company with a kinase inhibitor pipeline (cabozantinib). A relevant broader incumbent for benchmarking small-molecule targeted oncology development.
• Bayer: Markets copanlisib (Aliqopa), a pan-PI3K inhibitor approved for follicular lymphoma. A broad incumbent competing in the PI3K oncology space.

Direct peers

• Infinity Pharmaceuticals: Developed duvelisib alongside Verastem and historically pursued PI3K delta/gamma programs. A direct historical competitor in PI3K drug development.
• TG Therapeutics: Developed umbralisib (Ukoniq), a dual PI3K delta/CK1 epsilon inhibitor. Comparable as a small-cap biotech pursuing selective PI3K inhibition in oncology and inflammatory indications.
• Verastem: Developed and markets duvelisib (Copiktra), a dual PI3K delta/gamma inhibitor. A small-cap oncology company that closely mirrors Pathway's positioning as a focused PI3K developer.

Emerging players

• PIQUR Therapeutics: Swiss clinical-stage company developing selective and balanced PI3K/mTOR inhibitors for oncology. A focused emerging player with directly comparable mechanism of action.
• Relay Therapeutics: Clinical-stage precision oncology company with PI3K alpha programs (e.g., RLY-2608). A newer entrant demonstrating continued pharma and investor interest in selective PI3K inhibitors.
• Karus Therapeutics: UK-based developer of PI3K-beta and PI3K-delta selective inhibitors for cancer and inflammatory diseases. Closely comparable dual-indication strategy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pathway Therapeutics